Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1800]

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Updates in localised prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo'...

ASCO GU 2026: Updates in localised prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )

ASCO GU 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez...

ASCO GU 2026: Latest updates in mRCC ( Dr Toni Choueiri, Prof Viktor Grünwald, Dr Stephanie Berg, Dr Cristina Suárez and Dr Guillermo de Velasco )

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia,

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia, )

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or...

Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA

$Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma ( Dr Lorenzo Falchi - Memorial Sloan Kettering Cancer Center, New York, USA )$

Tepotinib in second line NSCLC treatment

Dr Antonio Passaro and Prof Raffaele Califano

Tepotinib in second line NSCLC treatment ( Dr Antonio Passaro and Prof Raffaele Califano )

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric...

Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer ( Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada )

Consolidation treatment delays do not compromise survival in MRD-negative adult...

Prof Bhavana Bhatnagar - WVU Medicine Wheeling Hospital, Wheeling, USA

Consolidation treatment delays do not compromise survival in MRD-negative adult ALL ( Prof Bhavana Bhatnagar - WVU Medicine Wheeling Hospital, Wheeling, USA )

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in...

Dr Anjali Advani - Cleveland Clinic, Cleveland, USA

Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL ( Dr Anjali Advani - Cleveland Clinic, Cleveland, USA )

Tec-Dara significantly improves PFS and OS compared to SoC in relapsed...

Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA

$Tec-Dara significantly improves PFS and OS compared to SoC in relapsed/refractory multiple myeloma ( Dr Luciano Costa - University Of Alabama At Birmingham, Birmingham, USA )$

Black patients show inferior survival despite similar cytogenetics and...

Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine...

Black patients show inferior survival despite similar cytogenetics and treatment response ( Prof Shella Saint Fleur-Lominy - University of Maryland School of Medicine, Baltimore, USA )

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and...

Prof Jennifer Woyach - The Ohio State University, Columbus, USA

Rocbrutinib shows strong responses in resistant CLL, including BTKi- and venetoclax-exposed patients ( Prof Jennifer Woyach - The Ohio State University, Columbus, USA )

More from ecancer